Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
133 hedge funds and large institutions have $1.32B invested in Eagle Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 52 increasing their positions, 37 reducing their positions, and 13 closing their positions.
108% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 13
41% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 37
27% more capital invested
Capital invested by funds: $1.04B → $1.32B (+$280M)
12% more funds holding
Funds holding: 119 → 133 (+14)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
36% less call options, than puts
Call options by funds: $6.24M | Put options by funds: $9.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$36M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$15M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$14.9M |
| 4 |
CM
Castleark Management
Chicago,
Illinois
|
+$10.5M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$7.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$17.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17M |
| 3 |
WSA
Wall Street Associates
Lajolla,
California
|
-$6.69M |
| 4 |
Two Sigma Investments
New York
|
-$5.74M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$4.88M |
EGRX Hedge Fund Activity: Q4 2015 in Review
133 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2015, worth a combined $1.32B — up 27% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new EGRX positions and 13 closed out — a net gain of 14 holders — while 52 added to existing stakes and 37 trimmed.
The largest buyer was Janus Henderson Investors US, adding an estimated $36M. The largest seller was Highland Capital Management (Texas), exiting entirely with an estimated $17.7M sold.
- 133 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2015, up from 119 in Q3 2015.
- Funds reported $1.32B of Eagle Pharmaceuticals, Inc. stock for Q4 2015, up 27% quarter-over-quarter.
- 27 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2015 and 13 closed out, a net change of +14 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2015 was Janus Henderson Investors US, an estimated $36M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q4 2015 was Highland Capital Management (Texas), an estimated $17.7M sold.
Based on aggregated 13F filings for Q4 2015.